338 related articles for article (PubMed ID: 27090289)
1. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
Olmsted GA; Farrelly J; Post GS; Smith J
J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
Holtermann N; Kiupel M; Hirschberger J
Vet Comp Oncol; 2017 Jun; 15(2):632-640. PubMed ID: 26762970
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
10. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
11. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Rosario CO; Musser ML; Yuan L; Mochel JP; Talbott J; Johannes CM; Berger EP
Can Vet J; 2023 Dec; 64(12):1143-1148. PubMed ID: 38046430
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
15. Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.
de Vos J; Ramos Vega S; Noorman E; de Vos P
Vet Comp Oncol; 2012 Sep; 10(3):206-13. PubMed ID: 22236048
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.
Dedeaux AM; Langohr IM; Boudreaux BB
Can Vet J; 2018 Jul; 59(7):751-754. PubMed ID: 30026621
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
19. Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005).
Gill VL; Bergman PJ; Baer KE; Craft D; Leung C
Vet Comp Oncol; 2008 Mar; 6(1):55-64. PubMed ID: 19178663
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
